Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNC Transplantation in ALS
NCT01984814Phase 2Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Dec 2008
- Primary completion
- Aug 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in amyotrophic lateral sclerosis (ALS), sponsored by NeuroGen Brain & Spine Institute. Planned start Dec 2008; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01984814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01984814.